French pharmaceutical company Valneva has completed the first clinical trial of the vaccine against Lyme disease (tick-borne borreliosis). Every year more than 600 thousand people are affected by this. In Europe, the number of cases increases by 14% per year.
The US Food and Drug Administration (FDA) has previously announced plans to speed up the approval of the vaccine against Lyme disease. The Valneva received approval from the regulatory agency through a program known as Fast Track, to go to a larger trial version in early 2018. This kind of approach can reduce the time needed for vaccine development by several years. According to the company’s forecasts, the vaccine may appear on the market in 5 years.
According to early clinical studies, the effectiveness of the vaccine is up to 96%.
As David Lawrence, CFO of Valneva said, the company invested $ 350 million in vaccine development.
Lyme disease (tick-borne borreliosis) is an infectious disease caused by Borrelia burgdorferi spirochetes and transmitted by ticks. This disease is characterized by a tendency to chronic and recurrent course and a primary lesion of the skin, nervous system, musculoskeletal system, and heart.